Ifm Therapeutics (United States)

First‐in‐human safety, tolerability, and pharmacokinetic results of DFV890, an oral low‐molecular‐weight NLRP3 inhibitor

Ewa Gatlik, Beata Mehes, Emilie Voltz et al. · Clinical and Translational Science · 2024 · 52 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +13

Discovery of DFV890, a Potent Sulfonimidamide-Containing NLRP3 Inflammasome Inhibitor

Dong-Ming Shen, Kate F. Byth, Damien Bertheloot et al. · Journal of Medicinal Chemistry · 2025 · 34 citations

Life Sciences, Medicinal Chemistry, Pharmacology +17

The Specific NLRP3 Antagonist IFM-514 Decreases Fibrosis and Inflammation in Experimental Murine Non-Alcoholic Steatohepatitis

Sandra Torres, Maximilian Joseph Brol, Fernando Magdaleno et al. · Frontiers in Molecular Biosciences · 2021 · 24 citations · Full text

Veterinary Medicine, Immunology, Pharmacology +17

Efficacy of novel selective NLRP3 inhibitors in human and murine retinal pigment epithelial cells

Luping Wang, Sarah Schmidt, Petra P. Larsen et al. · Journal of Molecular Medicine · 2019 · 23 citations

Life Sciences, Cell Biology, Pharmacology +8

Reconciling Human-Canine Differences in Oral Bioavailability: Looking beyond the Biopharmaceutics Classification System

Marilyn N. Martinez, Ayman El‐Kattan, Elias Gebru Awji et al. · The AAPS Journal · 2019 · 11 citations

Pharmacy, Pharmacokinetics, Pharmacology +16